• 1
    Vickers A, Bennette C, Steineck G et al. Individualized estimation of the benefit of radical prostatectomy from the scandinavian prostate cancer group randomized trial. Eur Urol 2012; 62: 204209
  • 2
    Ploussard G, Azancot V, Nicolaiew N et al. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. BJU Int 2010; 106: 12931297
  • 3
    Finne P, Fallah M, Hakama M et al. Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 31023108
  • 4
    Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 12481253
  • 5
    Outzen M, Brasso K, Martinussen N et al. Prostate cancer in Denmark 1978–2009. Acta Oncol 2012; [Epub ahead of print]
  • 6
    Mukai TO, Bro F, Pedersen KV, Vedsted P. [Use of prostate-specific antigen testing]. Ugeskr Laeger 2010; 172: 696700
  • 7
    Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 10791092
  • 8
    Brasso K, Ingimarsdottir IJ, Thomassen L, Friis S, Iversen P. [Prostate cancer in Denmark 1943–2002]. Ugeskr Laeger 2007; 169: 129132
  • 9
    Bray F, Klint A, Gislum M et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol 2010; 49: 644654
  • 10
    Heggestad T, Jonsson PM, Danneskiold-Samsoe B, Leisti S. [Prostate cancer in Scandinavia. Variations in practice and attitude to radical treatment]. Nord Med 1993; 108: 104106
  • 11
    Wehrberger C, Berger I, Willinger M, Madersbacher S. Radical prostatectomy in Austria from 1992 to 2009: an updated nationwide analysis of 33 580 cases. J Urol 2012; 187: 16261631
  • 12
    Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012; 18: 67426747
  • 13
    Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21: 1922
  • 14
    Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 12281242
  • 15
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974
  • 16
    Montorsi F, Wilson TG, Rosen RC et al. Best Practices in Robot-assisted Radical Prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol 2012; 62: 368381
  • 17
    Boorjian SA, Eastham JA, Graefen M et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012; 61: 664675
  • 18
    Roder MA, Berg KD, Gruschy L, Brasso K, Iversen P. First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer 2011; 2011: 236357
  • 19
    Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 43004305
  • 20
    Veenema RJ, Gursel EO, Lattimer JK. Radical retropubic prostatectomy for cancer: a 20-year experience. J Urol 1977; 117: 330331
  • 21
    Gerber GS, Thisted RA, Scardino PT et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615619
  • 22
    Qi P, Tsivian M, Abern MR et al. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5–4 ng/ml. Urol Oncol 2012; [Epub ahead of print]. doi: 10.1016/j.urolonc.2012.06.003
  • 23
    Thellenberg C, Malmer B, Tavelin B, Gronberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003; 169: 13451348
  • 24
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 17081717
  • 25
    Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203213
  • 26
    Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528534
  • 27
    Schmitges J, Trinh QD, Bianchi M et al. The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. Int Urol Nephrol 2012; 44: 799806
  • 28
    Vickers A, Savage C, Bianco F et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol 2011; 59: 317322
  • 29
    Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 13541360